Fenebrutinib for Multiple Sclerosis (FENopta Trial)

"Indeed, clinicaltrials.gov shows the trial is still recruiting participants since it was first published on March 1st of 2022 and last updated in November 10th of 2022. A total of 102 patients are being accepted across two sites."

"This clinical trial is open to 102 individuals aged between 18 and 55 that have been diagnosed with multiple sclerosis. Furthermore, they must meet the revised McDonald Criteria for RMS as well as having a EDSS score of 0-5.5 at screening. For female patients capable of bearing children, abstinence or contraception will be mandated whilst male participants are also required to abstain from sexual intercourse or use birth control measures in addition to not donating sperm."

"Supported by a Phase 2 trial, the safety of fenebrutinib is estimated to be moderate at a score of 2. Currently, no data exists that proves its efficacy."

"Clinicaltrials.gov affirms that this medical investigation is actively recruiting subjects; the study was first advertised on March 1st 2022 and recently revised on November 10th 2022."

"This clinical trial has an age-based eligibility threshold, wherein individuals above 18 years old and below 55 can be accepted."

"Fenebrutinib is the subject of 4 live clinical trials spanning 41 countries and 168 cities. The initial exploration into this medication, conducted by Hoffmann-La Roche in 2020, involved 946 participants and reached its final approval step at Phase 3. Since then, a further 2698 experiments have been carried out with fenebrutinib."

"At present, fenebrutinib is the focus of 4 live medical studies with 3 in their final phase. Most of these clinical trials are held in Cali and Liguria, however 522 different sites around the world have experiments running concerning this medication."